Black Diamond Therapeutics (BDTX) Stock Price, News & Analysis

Company Overview

Black Diamond Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing precision medicines for genetically defined cancers. The company uses its proprietary MasterKey platform to identify and develop small-molecule therapies designed to address oncogenic mutations across multiple tumor types, including alterations that may be difficult to target with conventional approaches.

Black Diamond’s pipeline has included brain-penetrant therapies for cancers affecting the central nervous system. Its lead programs have focused on molecularly targeted treatments such as BDTX-1535, an investigational EGFR inhibitor being evaluated in cancers with specific EGFR alterations, and BDTX-4933, an investigational pan-RAF inhibitor intended to target tumors driven by aberrant MAPK pathway signaling. These programs are being studied in clinical trials, and their safety and effectiveness have not been established for marketing.

Founded in 2017 and headquartered in Cambridge, Massachusetts, Black Diamond conducts research and clinical development activities aimed at serving patients with biomarker-defined solid tumors. The company is led by Mark V. Glickman, who serves as chief executive officer. Black Diamond Therapeutics trades on the Nasdaq under the symbol BDTX.

Key Stats

• Today's Range: $1.65 to $1.77
• 50-Day Range: $1.68 to $2.27
• 52-Week Range: $1.60 to $4.94
• Volume: 1.10 million shs
• Average Volume: N/A
• Market Capitalization: N/A
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $11.00
• Consensus Rating: Moderate Buy

Black Diamond Therapeutics Stock Analysis - MarketRank™

Black Diamond Therapeutics scored higher than 54% of companies evaluated by MarketBeat, and ranked 362nd out of 905 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.1 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Black Diamond Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.60, and is based on no strong buy ratings, 7 buy ratings, 2 hold ratings, and 1 sell rating.

Upside Potential

Black Diamond Therapeutics has a consensus price target of $11.00, representing about 528.6% upside from its current price of $1.75.

Amount of Analyst Coverage

Black Diamond Therapeutics has only been the subject of 4 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for Black Diamond Therapeutics are expected to decrease in the coming year, from ($0.57) to ($1.03) per share.

Short Interest

• Score: 1.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

9.60% of the float of Black Diamond Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Black Diamond Therapeutics has a short interest ratio ("days to cover") of 7.33.

Change versus previous month

Short interest in Black Diamond Therapeutics has recently increased by 4.75%, indicating that investor sentiment is decreasing.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Black Diamond Therapeutics does not currently pay a dividend.

Dividend Growth

Black Diamond Therapeutics does not have a long track record of dividend growth.

News and Social Media

• Score: 3.9 / 5
• News Sentiment: 1.26

News Sentiment

Black Diamond Therapeutics has a news sentiment score of 1.26. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.69 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 3 news articles for Black Diamond Therapeutics this week, compared to 2 articles on an average week.

Search Interest

Only 3 people have searched for BDTX on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

MarketBeat Follows

2 people have added Black Diamond Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days.

Company Ownership

• Score: 1.0 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Black Diamond Therapeutics insiders have not sold or bought any company stock.

Percentage Held by Insiders

9.29% of the stock of Black Diamond Therapeutics is held by insiders.

Percentage Held by Institutions

95.47% of the stock of Black Diamond Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Company Calendar

• Last Earnings: 8/05/2026
• Today: 10/27/2026
• Next Earnings (Estimated): 11/05/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:BDTX
• CIK: 1701541
• Web: www.blackdiamondtherapeutics.com
• Phone: (617) 417-5868
• Fax: N/A
• Employees: 21
• Year Founded: 2017

Price Target and Rating

• Average Price Target for Black Diamond Therapeutics: $11.00
• High Price Target: $14.00
• Low Price Target: $8.00
• Potential Upside/Downside: +528.6%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.60
• Research Coverage: 10 Analysts

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: N/A
• Free Float: 52,117,000
• Market Cap: N/A
• Optionable: Optionable
• Beta: N/A